Kilitch Drugs (India) Ltd
NSE:KILITCH
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
252.4
460.95
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Kilitch Drugs (India) Ltd
Cash & Cash Equivalents
Kilitch Drugs (India) Ltd
Cash & Cash Equivalents Peer Comparison
DRREDDY
CIPLA
SUNPHARMA
ZYDUSLIFE
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
K
|
Kilitch Drugs (India) Ltd
NSE:KILITCH
|
Cash & Cash Equivalents
₹196.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cash & Cash Equivalents
₹7.1B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Cash & Cash Equivalents
₹8.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
7%
|
CAGR 10-Years
17%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cash & Cash Equivalents
₹105.2B
|
CAGR 3-Years
18%
|
CAGR 5-Years
8%
|
CAGR 10-Years
3%
|
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Cash & Cash Equivalents
₹11.1B
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Cash & Cash Equivalents
₹8.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
See Also
What is Kilitch Drugs (India) Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
196.4m
INR
Based on the financial report for Jun 30, 2024, Kilitch Drugs (India) Ltd's Cash & Cash Equivalents amounts to 196.4m INR.
What is Kilitch Drugs (India) Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
32%
Over the last year, the Cash & Cash Equivalents growth was -2%. The average annual Cash & Cash Equivalents growth rates for Kilitch Drugs (India) Ltd have been 16% over the past three years , 32% over the past five years .
You don't have any saved screeners yet
